Biogen announces $5 billion buyback days after shelving Alzheimer’s trials

File photo: Michael LeClair, left, along with Kevin Fleurimond, inside manufacturing room of Biogen Idec.

Suzanne Kreiter | The Boston Globe | Getty Images

File photo: Michael LeClair, left, along with Kevin Fleurimond, inside manufacturing room of Biogen Idec.

Biogen said on Monday the idea might buy back shares worth $5 billion, days after its stock slumped on the drugmaker’s announcement to end two Alzheimer’s disease trials.

Biogen had lost more than $18 billion of its value last week after the company along with partner Eisai ended two late-stage trials of their experimental Alzheimer’s disease treatment, aducanumab.

Biogen shares, which lost 32.4 percent of their value since the company’s announcement on Thursday to scrap the trials, were up 1.5 percent before the opening bell on Monday.

The share buyback will be in addition to the approximately $1.7 billion remaining under the stock repurchase program authorized by its board in August 2018, the company said in a regulatory filing